Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Giredestrant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche's Oral SERD Flunks 1St-Line Breast Cancer Phase 3
    Roche's Oral SERD Flunks 1St-Line Breast Cancer Phase 3

    10 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/roches-oral-serd-flunks-phase-3-trial-first-line-breast-cancer

    FIERCE BIOTECH
    10 Mar 2026
    Share Share
    FDA accepts NDA for Roche’s giredestrant in ESR1-Mutated
    FDA accepts NDA for Roche’s giredestrant in ESR1-Mutated

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/20/3241682/0/en/FDA-accepts-New-Drug-Application-for-Roche-s-giredestrant-in-ESR1-mutated-ER-positive-advanced-breast-cancer.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Roche Eyes Busy 2026 Despite Vabysmo Miss, Tecentriq Flop
    Roche Eyes Busy 2026 Despite Vabysmo Miss, Tecentriq Flop

    29 Jan 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study

    FIERCE PHARMA
    29 Jan 2026
    Share Share
    Roche Links SERD to 30% Breast Cancer Risk Reduction in Phase 3
    Roche Links SERD to 30% Breast Cancer Risk Reduction in Phase 3

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203134/0/en/Roche-s-giredestrant-reduced-risk-of-invasive-disease-recurrence-or-death-by-30-in-ER-positive-early-stage-breast-cancer.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Genentech's Giredestrant Cuts Er-Positive Breast Cancer
    Genentech's Giredestrant Cuts Er-Positive Breast Cancer

    10 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251210478442/en/Genentechs-Giredestrant-Reduced-Risk-of-Invasive-Disease-Recurrence-or-Death-by-30-in-ER-positive-Early-Stage-Breast-Cancer

    BUSINESSWIRE
    10 Dec 2025
    Share Share
    Genentech's Giredestrant Shows Superior iDFS in Breast Cancer
    Genentech's Giredestrant Shows Superior iDFS in Breast Cancer

    18 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251117114377/en/Genentechs-Giredestrant-Becomes-the-First-Oral-SERD-to-Show-Superior-Invasive-Disease-Free-Survival-in-Early-Breast-Cancer

    BUSINESSWIRE
    18 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.